Kintor Pharma's KX-826 Shows Statistically Significant Hair Growth in US Phase II Trial for Male Pattern Baldness
核心洞察
Kintor Pharma (搜索)'s KX-826 demonstrated statistically significant hair growth improvement in a US Phase II trial for male androgenetic alopecia (搜索), with the 0.5% twice-daily dose increasing hair count by approximately 10 hairs per cm² after 24 weeks (P=0.0088).
The randomized, double-blind, placebo-controlled study enrolled 123 male patients with moderate to severe hair loss, showing a clear dose-response relationship and favorable safety profile with only mild local scalp sensitivity reported.
The company plans to initiate Phase III trials globally following FDA meetings, with 0.5% twice-daily identified as the optimal dosing regimen for advanced development.
Kintor Pharmaceutical Limited announced successful completion of its Phase II clinical trial evaluating KX-826 for male androgenetic alopecia (搜索) (AGA) in the United States, with results demonstrating statistically significant and clinically meaningful hair growth improvements. The biotechnology company is now preparing for FDA meetings and plans to commence Phase III trials globally.
Trial Design and Patient Population
The Phase II study was designed as a randomized, double-blind, placebo-controlled, parallel group trial to evaluate KX-826's efficacy and safety for treating male AGA. The trial enrolled 123 male patients classified as stage III vertex, IV, or V on the Hamilton-Norwood scale, representing moderate to severe hair loss patterns.
Among the enrolled patients, 93 were randomly assigned to active treatment groups receiving KX-826 at different dosages: 0.25% once daily, 0.5% once daily, and 0.5% twice daily. The remaining 30 patients were assigned to placebo groups with corresponding dosing frequencies.
Primary Efficacy Results
The trial's primary endpoint measured target area non-vellus hair count (TAHC), with the most significant results observed in the 0.5% twice-daily treatment group. After 24 weeks of treatment, this group demonstrated an increase of approximately 10 hair counts per cm² compared to baseline, achieving statistical significance with a p-value of 0.0088.
KX-826 showed improvement in TAHC versus placebo across all dosage groups, with a clear dose-response relationship observed. The results indicated that KX-826 promotes hair growth clinically in male AGA patients, with the 0.5% twice-daily regimen identified as the optimal dose for future development.
Safety Profile
The treatment demonstrated a favorable safety profile throughout the 24-week study period. Most treatment-emergent adverse events (TEAEs) were characterized as mild and involved local scalp sensitivity, with occurrence rates similar to placebo groups. Notably, no TEAEs resulted in patient withdrawal from the trial, and no deaths were reported during the study period.
Global Development Strategy
The successful US Phase II results align with previous findings from Kintor Pharma (搜索)'s Phase II trial in China, where the same 0.5% twice-daily dosing regimen was determined to be optimal. This consistency across geographic regions supports the company's global development strategy for KX-826.
The company has multiple ongoing clinical trials for KX-826 across different patient populations. On December 1, 2022, Kintor Pharma (搜索) announced that the primary endpoint of its Phase II clinical trial in China for female AGA treatment was successfully met. Additionally, enrollment for the Phase III trial of KX-826 in China for male AGA treatment was completed on March 28, 2023, with top-line data expected in the fourth quarter of 2023.
Next Steps
Following the successful Phase II completion, Kintor Pharma (搜索) is preparing for subsequent FDA meetings to discuss the trial results and regulatory pathway forward. The company intends to commence Phase III clinical trials in the US and globally, using the validated 0.5% twice-daily dosing regimen as the recommended dose for advanced-stage development.
The positive results represent a significant milestone for Kintor Pharma (搜索)'s androgen receptor (搜索)-focused therapeutic pipeline, addressing an area of substantial unmet medical need in dermatology and aesthetic medicine.